EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX‐351) for the Treatment of Adults with Newly Diagnosed, Therapy‐Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia‐Related Changes

On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML). Vyxeos was designated as an orphan medicinal product o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Tzogani, Kyriaki, Penttilä, Karri, Lapveteläinen, Tuomo, Hemmings, Robert, Koenig, Janet, Freire, João, Márcia, Silva, Cole, Susan, Coppola, Paola, Flores, Beatriz, Barbachano, Yolanda, Roige, Silvia Domingo, Pignatti, Francesco
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Regulatory Issues: EMA
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485353/
https://ncbi.nlm.nih.gov/pubmed/32282100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0785
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi